IVVD
InvivydDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical data or a meaningful licensing/partnership deal de-risks the pipeline, prompting multiple expansion from a low valuation and material upside versus the anchor.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Need for dilutive financing / insufficient cash runway
Momentum
31
Value
41
Sentiment
56
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.14 · Bull $1.71 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum31 · Δ7d -
Value41 · Δ7d +0.1
Sentiment56 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
31
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
56
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 30.9 / Value 41.1 / Sentiment 56.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$359.42M
Beta
0.62
Shares Out
277.06M
P/E (TTM) · Derived
-0.9
P/S (TTM)
14.12
P/FCF (TTM) · Derived
-2.14
Rev YoY
+41.2%
EPS YoY
+87.9%
Gross Margin
+93.3%
Op Margin
-124.4%
Net Debt
-$69.35M
Current Ratio
2.47
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology